AllCells-Boston to serve as company’s second US-based hematologic tissue collection site, increasing assurance of supply and accelerating delivery of fresh products to eastern region and global life science researchers      


POSTED August 24, 2016 07:00 AM Eastern Daylight Time

ALAMEDA, Calif. – (BUSINESS WIRE) – AllCells, LLC, (the “company”) today announced signing a Clinical Operations lease agreement, and commencing construction of its new tissue collection facility located in metropolitan Boston, MA. The east coast facility, expected to be operational January 2017, is optimally situated to enhance service to life science researchers located throughout US east coast, Europe, and rest of world.

AllCells-Boston significantly expands the company’s total production capacity to serve a growing market demand for its products, initially focusing on manufacturing fresh hematologic tissue such as Whole Bone Marrow, Leukapheresis products (Leuko Paks), and Whole Peripheral Blood sourced from qualified, clinically healthy human donors. The new operation will also be able to ‘mobilize’ healthy donor volunteers using mobilization agents such as r-GCSF (Neupogen®) and/or Plerixafor (Mozobil®) to stimulate hematopoietic stem cell (HSC) migration into peripheral blood for subsequent collection/packaging.

In a secondary phase of operational planning, AllCells-Boston will have potential to expand its capabilities to purify and cryopreserve a selection of primary cell types for in-vitro research use, and also produce CliniCells™ clinical-grade products for further manufacturing of allogeneic cell and gene therapies. The company will apply the same proprietary IRB-approved collection protocols originally developed at its Alameda, CA (San Francisco Bay area) facilities to ensure consistently high quality products are produced and delivered to customers worldwide.

AllCells’ President & CEO, Jay Tong, M.D, commented, “Our customers depend on these hematology and immunology primary cell products to support their cell-based assay applications in drug discovery and preclinical development work-flows. AllCells-Boston strengthens our business continuity capability enabling us to fill customer orders from two different collection sites. The second site expands the company’s overall donor repository thereby providing customers access to a larger and more diverse human donor pool for procuring relevant phenotypes important for their specific cell-based assay applications. The placement of our tissue collection facilities in Boston, MA together with current Alameda, CA facilities helps assure customers will receive fresh products having the highest possible cell viability”.

AllCells maintains a sizeable database of HLA-typed human donors, and this repository is constantly increasing. For more information about the availability of research-grade or CliniCells™ clinical-grade products, contact us at 1-888-535-3444, or 1-510-521-2600, and


About AllCells, LLC

AllCells is a biotechnology company dedicated to providing researchers and biomanufacturing organizations with high quality primary cells that enable drug discovery, preclinical development, and manufacturing of cell therapies. Leveraging its expertise in hematology and immunology cell isolations together with on-site hematologic tissue collection operations, AllCells maintains a large repository of donor profiles that can be qualified for various biomedical applications. Freshly collected tissue is immediately processed in contiguous manufacturing facilities to produce purified cell types having unparalleled quality and consistency. Cells are shipped worldwide, or fresh cells can be immediately utilized in fee-for-service cell-based assays (“Bioservices”) custom designed according to customer criteria. For more information, please visit


Wayne E. Vaz
Vice President,
Corporate Development

See official Business Wire release: here.